We are live on ! Find out more
TPST icon

Tempest Therapeutics

54 hedge funds and large institutions have $31.3M invested in Tempest Therapeutics in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $2K | Put options by funds: $1K

14% less funds holding

Funds holding: 6354 (-9)

25% less capital invested

Capital invested by funds: $41.9M → $31.3M (-$10.6M)

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

Holders
54
Holders Change
-9
Holders Change %
-14.29%
% of All Funds
1.35%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
9
Reduced
16
Closed
23
Calls
$2K
Puts
$1K
Net Calls
+$1K
Net Calls Change
-$19K

TPST Hedge Fund Activity: Q2 2017 in Review

54 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2017, worth a combined $31.3M — down 25% from $41.9M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of TPST and 14 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 9 added.

The largest buyer was Legal & General Group, adding an estimated $652K. The largest seller was BlackRock, cutting an estimated $2.04M.

  • 54 institutional investors held Tempest Therapeutics (TPST) as of Q2 2017, down from 63 in Q1 2017.
  • Funds reported $31.3M of Tempest Therapeutics stock for Q2 2017, down 25% quarter-over-quarter.
  • 14 funds opened new Tempest Therapeutics positions in Q2 2017 and 23 closed out, a net change of -9 holders.
  • The largest Tempest Therapeutics buyer in Q2 2017 was Legal & General Group, an estimated $652K added.
  • The largest Tempest Therapeutics seller in Q2 2017 was BlackRock, an estimated $2.04M sold.

Based on aggregated 13F filings for Q2 2017.